Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 6/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.47 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060236 | 0.90 | HDAC4 (0.51) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL12560110 | 0.85 | PADI1 (0.56) | — | |
| SCHEMBL10060237 | 0.84 | PDE4A (0.53) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL10060142 | 0.81 | KDM1A (0.58) | — | |
| SCHEMBL1009191 | 0.80 | HDAC4 (0.47) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL10060143 | 0.78 | PADI6 (0.62) | — | |
| SCHEMBL18941863 | 0.78 | HDAC4 (0.45) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL12560124 | 0.77 | PADI1 (0.52) | — | |
| SCHEMBL5130136 | 0.76 | HDAC1 (0.59) | HDAC4HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL28316169 | 0.76 | HDAC1 (0.59) | HDAC4HDAC3HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PADI4, PADI2, PADI3 | HDAC4 42/4885HDAC3 458/4885HDAC1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.